Tempus AI's growth and partnerships make it an attractive investment. See why TEM stock is a solid Buy due to its ...

Tempus AI (NASDAQ:TEM – Get Free Report)‘s stock had its “neutral” rating restated by investment analysts at Piper Sandler in a research report issued on Tuesday,Benzinga reports. They currently have ...

Fintel reports that on November 11, 2024, Stifel downgraded their outlook for Tempus AI (NasdaqGS:TEM) from Buy to Hold. ...

Stifel Nicolaus analyst Daniel Arias downgraded the rating on Tempus AI, Inc. Class A (TEM – Research Report) to a Hold yesterday, ...

Aliso Viejo-based Ambry Genetics Corp. on Nov. 4 announced an agreement to be acquired for $600 million by Tempus AI Inc.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, " Actionable structural variant ...

The firms said that the deal will provide access to Tempus' testing menu for healthcare providers at 800 cancer care locations that use Flatiron's OncoEMR platform.

Thank you, Briana. Good afternoon, and welcome to Tempus’ third quarter 2024 conference call. This afternoon, Tempus released results for the quarter ending September 30, 2024. Joining me today from ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced nine abstracts were accepted for presentation at the ...

CHICAGO, November 08, 2024--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced nine ...

Stifel has downgraded Tempus AI (NASDAQ:TEM) to hold from buy, citing valuation and uncertainty about core growth in 2025.